[Commentary on] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan Journal Article
| Author: | Sabbatini, P. |
| Article Title: | [Commentary on] Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan |
| Keywords: | survival analysis; disease progression; doxorubicin -- adverse effects; doxorubicin -- therapeutic use; recurrence -- prevention and control; ovarian neoplasms -- drug therapy; ovarian neoplasms -- mortality; female; topotecan -- therapeutic use; topotecan -- adverse effects |
| Journal Title: | Women's Oncology Review |
| Volume: | 1 |
| Issue: | 4 |
| ISSN: | 1473-3404 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2001-01-01 |
| Start Page: | 389 |
| End Page: | 390 |
| Language: | English |
| ACCESSION: | 2004132003 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Accession Number: 2004132003 -- Entry Date: 20040806 -- Revision Date: 20140808 -- Publication Type: journal article; abstract; commentary -- Original Study: Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore M, Lacave AJ -- Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan -- J CLIN ONCOL 2001; 19: 3312-22 -- Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 101128014. -- Source: cin20 |
MSK Authors
-
262Sabbatini